Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deuremidevir hydrobromide dose-ranging trial in hospitalized infants with RSV infection
ChiCTR2400079559Phase 2Not yet recruiting
- Sponsor
- Shulan Health
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deuremidevir in respiratory syncytial virus disease (RSV) (4 arms), sponsored by Shulan Health. Primary endpoints: Incidence of adverse events during the study, Subject withdrawals due to adverse events and 11 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
deuremidevir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on ChiCTR2400079559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079559.